NCT06397573
Ablative Stereotactic MR-Guided Adaptive Reirradiation
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 21 words Show 5 more changesShow less
- Trial completed
- Final enrollment: 11 participants (planned 10)
- Study completion date changed from estimate of Jun 2027 to Aug 20, 2026
- Secondary endpoints: details revised at 3 of 4 entries
- Publications: details revised at 7 of 7 entries
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date: Jun 2027 to Aug 2026
- Site details revised
- Collaborators shortened, about 3 words
- Notable Eligibility criteria shortened, about 9 wordsv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jun 2024 to Jun 5, 2024
- Site details revised
- Notable Phase: Phase 1 to Not applicable
- Study title shortened, about 4 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Grade 3 or higher acute toxicity
Timeframe: 1 year
Grade 5 toxicity
Timeframe: 1 year
Secondary (4)
Freedom from local progression (FFLP)
Overall survival (OS)
Grade 3 or higher late toxicity
Quality of life (QOL)
Arms and interventions
Ablative ReirradiationExperimental
Radiation: Reirradiation
Sites
1 site in 1 country
- Miami Cancer Institute at Baptist Health South FloridaMiami, Florida, United States